How a peptide prescription actually works
Every peptide taken as a drug is prescription-only in the United States. That single sentence hides the part that decides your options: a prescription can be legal to write and still impossible to fill. Here is which is which, and why.
There is no over-the-counter peptide injection
Nothing you inject is sold legally over the counter at a US pharmacy. Anything taken as a medicine needs a licensed prescriber, which is the one part of this subject that has not moved in three years.
One class never needed a prescriber at all. Cosmetic peptides — argireline, matrixyl and the rest — go into serums you buy in a shop, because they are not sold as drugs and no approval or prescription exists for them to need. Everything else on this page is about peptides taken as medicine.
The peptides you can buy without a prescription are the ones labelled “for research use only” or “not for human consumption.” That wording is not a loophole a knowing buyer steps through — it is the seller stating they are not claiming to sell a drug, which is also how they avoid the manufacturing and purity rules that apply to one. Nobody has tested what is in the vial, and nobody is accountable if it is not what the label says.
One thing that surprises people: these are not controlled substances. A prescriber needs no DEA registration for sermorelin or semaglutide the way they would for oxycodone. Human growth hormone is the exception, with its own federal criminal restrictions dating to 1988. The pressure on this market comes from the FDA, not the DEA — it is about manufacturing and approval status, not about handling.
Only two of them end in a filled prescription
- FDA-approved. Semaglutide, tirzepatide, liraglutide, tesamorelin for one narrow indication, and PT-141. Trialled, labelled, and dispensed through ordinary retail or specialty pharmacies.
- Legally compoundable. Sermorelin is the clean example: a prescriber writes it for you specifically, a 503A compounding pharmacy prepares that prescription, you receive it.
- Neither prohibited nor permitted. BPC-157, TB-500, CJC-1295, ipamorelin and others. (GHK-Cu is the exception worth knowing: its non-injectable forms sit in Category 1, which permits compounding, and the same molecule is sold over the counter in skin and hair products.) This is the bucket that confuses everyone, and it is covered below.
- Sold as research chemicals. Outside the system entirely, and a large share of what is actually being injected in this country.
Why the third bucket is a dead end today
These were widely compounded until late 2023, when the FDA moved seventeen substances to a category that prohibited it. Since then the list has been coming apart: five were referred to the agency’s compounding advisory committee in September 2024 and are still pending, twelve more were released in April 2026, and the committee met that July and recommended most of the batch it reviewed for the permitted list.
Here is the trap. Coming off the prohibited list does not make a substance compoundable. It removes a stated ban; only being placed on the permitted list makes a pharmacy able to work with it, and that placement takes rulemaking the FDA has not started. A committee recommendation is a recommendation. So on paper, BPC-157 is authorized for nobody: it is off the prohibited list, not on the permitted one. In practice clinicians do write it and some compounding pharmacies do prepare it, which is what our guide describes — whether yours will is a question for that pharmacy, not one the list answers. The people who cannot find a pharmacy at all are the ones who end up on overseas sites.
Most of this now happens over telehealth
The shape is the same at every platform. You fill in an intake — history, medications, weight, goals, sometimes labs. You are matched to a clinician licensed in your state, which is why state matters and why our state checker exists. They review the file, either asynchronously or on a video call, and if they judge the peptide appropriate they route the prescription to the pharmacy that platform works with.
Asynchronous review is faster and cheaper and most states allow it. Some state medical boards argue it does not meet the standard of care for compounded injectables; that argument is unresolved. Worth knowing which model you are buying: the provider pages say which each one runs.
The clinician who signs carries the legal responsibility, not the platform that introduced you. And the pharmacy differs by bucket — approved drugs come from a retail or specialty pharmacy, compounded ones from a 503A that specialises in it. A CVS will not have sermorelin. This market runs on infrastructure parallel to the retail one, which is the single thing patients most often misunderstand about it.
Insurance follows the bucket, not the diagnosis
An approved drug used on-label is eligible for coverage, subject to the usual formulary and prior-authorisation fight. For weight management specifically the picture is patchier, and plenty of employer plans exclude the GLP-1 class outright. Compounded peptides are essentially never covered: insurance pays for approved drugs in approved indications, so sermorelin is cash. Budget from what this actually costs rather than from a copay.
Off-label is legal — for approved drugs
A physician may prescribe an approved drug for an indication that is not on its label, and much of medicine works this way. What that latitude does not cover is an unapproved peptide: there is no label to be off of. “Off-label” and “unapproved” get used as if they were the same permission, and they are not.
Which gives you one clean question to ask any clinic. Not “can you prescribe it” but “which pharmacy fills it, and under what authority” — a written prescription nobody can legally fill is not access.
For the full regulatory picture — the dated timeline of the compounding lists, the 503A and 503B distinction, the GLP-1 shortage window and how it closed, the litigation, and the open FDA docket — read the long version on PeptideWellness.
This explainer is educational and not legal or medical advice, and the compounding lists change. See our Medical Disclaimer.
Fuel your protocol with
the latest research + reviews
Independent updates on peptide therapy, breaking news from compounding pharmacies, and exclusive guides — straight to your inbox.
